Journal article
Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
Advances in hematology, Vol.2011, pp.656013-7
2011
DOI: 10.1155/2011/656013
PMCID: PMC3112508
PMID: 21687649
Abstract
A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.
Details
- Title: Subtitle
- Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
- Creators
- Bhanu Vakkalanka - Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USABrian K Link - Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
- Resource Type
- Journal article
- Publication Details
- Advances in hematology, Vol.2011, pp.656013-7
- DOI
- 10.1155/2011/656013
- PMID
- 21687649
- PMCID
- PMC3112508
- NLM abbreviation
- Adv Hematol
- ISSN
- 1687-9104
- eISSN
- 1687-9112
- Publisher
- Hindawi Publishing Corporation
- Language
- English
- Date published
- 2011
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094403602771
Metrics
29 Record Views